Company Overview
Biofrontera Inc. operates as a biopharmaceutical company focused on the commercialization of pharmaceutical products designed for the treatment of dermatological conditions within the United States market. The company functions specifically within the Healthcare sector, categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on developing and selling specialized medical therapies rather than mass-market generic drugs. The organization maintains a workforce of 84 employees and holds a market capitalization of $9.54M, generating a Trailing Twelve Months (TTM) revenue of $41.70M. These valuation and revenue figures indicate that Biofrontera is a small-cap entity with a modest operational footprint, suggesting it is likely in a growth or development phase where revenue generation is prioritized alongside product expansion. The combination of a relatively low market cap and a specific focus on dermatological treatments positions the company as a niche player attempting to capture value in a specialized therapeutic area.
Financial Health
The company reported a TTM revenue of $41.70M, but this top-line figure contrasts sharply with a TTM net income of -$10,536,000 and an EBITDA of -$11,210,000, revealing a significant gap between gross sales and final profitability that points to high operating costs or substantial research and development expenditures. This negative income structure results in a Free Cash Flow of -$2,362,000, indicating that the company is currently burning cash to fund its operations and product development rather than generating surplus liquidity for shareholders. Despite the net loss, the company maintains a Gross Margin of 73.7%, which suggests a highly efficient cost of goods sold structure for its pharmaceutical products, while the Operating Margin stands at 26.7%, indicating that core business operations are relatively efficient before interest and taxes. However, the Profit Margin is -25.3%, confirming that the company is not currently profitable on a net basis. In terms of leverage, the company holds $6.40M in cash against $6.16M in debt, resulting in a Debt to Equity ratio of 58.79, which characterizes the balance sheet as moderately leveraged given the near-equality of liquid assets and liabilities. Short-term liquidity appears manageable with a Current Ratio of 1.52, suggesting the firm can cover its short-term obligations with its current assets. Furthermore, the Return on Equity is -141.3% and the Return on Assets is -28.0%, metrics that reveal that management is currently generating negative returns on both shareholder capital and the asset base, reflecting the early-stage financial realities of a loss-making biopharmaceutical firm.
Valuation Assessment
Valuation metrics for Biofrontera present a complex picture, as the Trailing P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is recorded at -3.56, implying that the market expects earnings to remain negative or that valuation models are relying on non-traditional multiples for this specific stock. The Price to Book ratio is 0.91, indicating that the market values the company at approximately 91% of its book value, suggesting no premium over net assets and potentially reflecting investor caution regarding future profitability. Alternative valuation metrics include a Price to Sales ratio of 0.23 and an EV/EBITDA of -0.83, which suggest the stock is priced very cheaply relative to its sales volume, though the negative EV/EBITDA reinforces the lack of current earnings generation. The stock has traded between a 52-Week High of $1.19 and a 52-Week Low of $0.54, with the current price situated within this range, reflecting significant volatility typical of small-cap biotech stocks. The Beta is 0.63, indicating that the stock's price volatility is lower than the broader market, moving less aggressively than the S&P 500 during periods of market fluctuation.
Growth & Income
Biofrontera has demonstrated robust expansion in its top line with a Revenue Growth (YoY) of 36.2%, whereas the Earnings Growth (YoY) is N/A due to the company's negative net income position. The divergence between strong revenue growth and negative earnings growth is typical for pharmaceutical companies in development stages, implying that the company is successfully scaling sales volume but has yet to achieve the operational efficiencies or product revenue milestones required to turn a profit. Regarding income distribution, the company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This lack of dividend payments is consistent with the company's strategy of reinvesting all available earnings and cash reserves back into the business to fund research, development, and commercialization efforts rather than distributing income to shareholders. Consequently, the overall growth and income profile is characterized by high revenue expansion and zero current income distribution, relying entirely on future product success and potential profitability to generate returns for investors.